BR112023021803A2 - Composição farmacêutica compreendendo o composto smtp-7 - Google Patents
Composição farmacêutica compreendendo o composto smtp-7Info
- Publication number
- BR112023021803A2 BR112023021803A2 BR112023021803A BR112023021803A BR112023021803A2 BR 112023021803 A2 BR112023021803 A2 BR 112023021803A2 BR 112023021803 A BR112023021803 A BR 112023021803A BR 112023021803 A BR112023021803 A BR 112023021803A BR 112023021803 A2 BR112023021803 A2 BR 112023021803A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical composition
- smtp
- compound
- treatment
- additive
- Prior art date
Links
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 4
- CRNDCHORWGDFGR-CLUVFYJOSA-N SMTP-7 Natural products CC(=CCCC(=CCC[C@]1(C)Oc2c(C[C@H]1O)c(O)cc3C(=O)N(CCC[C@@H](N4Cc5c6O[C@@](C)(CCC=C(C)CCC=C(C)C)[C@H](O)Cc6c(O)cc5C4=O)C(=O)O)Cc23)C)C CRNDCHORWGDFGR-CLUVFYJOSA-N 0.000 title abstract 3
- CRNDCHORWGDFGR-UHFFFAOYSA-N orniplabin Natural products C1C(O)C(C)(CCC=C(C)CCC=C(C)C)OC2=C1C(O)=CC(C1=O)=C2CN1C(C(O)=O)CCCN1CC2=C3OC(CCC=C(C)CCC=C(C)C)(C)C(O)CC3=C(O)C=C2C1=O CRNDCHORWGDFGR-UHFFFAOYSA-N 0.000 title abstract 3
- 150000001875 compounds Chemical class 0.000 title abstract 2
- CRNDCHORWGDFGR-PXTWCNKMSA-N (2s)-2,5-bis[(2s,3s)-2-[(3e)-4,8-dimethylnona-3,7-dienyl]-3,5-dihydroxy-2-methyl-7-oxo-4,9-dihydro-3h-pyrano[2,3-e]isoindol-8-yl]pentanoic acid Chemical compound C1[C@H](O)[C@](C)(CC\C=C(/C)CCC=C(C)C)OC2=C1C(O)=CC(C1=O)=C2CN1[C@H](C(O)=O)CCCN1CC2=C3O[C@](CC/C=C(C)/CCC=C(C)C)(C)[C@@H](O)CC3=C(O)C=C2C1=O CRNDCHORWGDFGR-PXTWCNKMSA-N 0.000 title 1
- 239000000654 additive Substances 0.000 abstract 2
- 230000000996 additive effect Effects 0.000 abstract 2
- 208000032382 Ischaemic stroke Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 206010008118 cerebral infarction Diseases 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 208000035475 disorder Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 239000003527 fibrinolytic agent Substances 0.000 abstract 1
- 230000000302 ischemic effect Effects 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Dermatology (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Abstract
composição farmacêutica compreendendo o composto smtp-7. este pedido fornece uma composição farmacêutica altamente segura contendo smtp-7 ou um sal, éster ou solvato do mesmo como um ingrediente ativo, em que a referida composição farmacêutica contém ainda um ou ambos de um aditivo básico e um aditivo anfipático. a presente invenção é útil para a prevenção ou tratamento de distúrbios isquêmicos, tais como infarto cerebral, incluindo acidente vascular cerebral isquêmico agudo, particularmente para o tratamento de pacientes que não podem ser tratados com drogas trombolíticas.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021070892 | 2021-04-20 | ||
| PCT/US2022/025462 WO2022226013A1 (en) | 2021-04-20 | 2022-04-20 | Pharmaceutical composition comprising the compound smtp-7 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112023021803A2 true BR112023021803A2 (pt) | 2024-01-23 |
Family
ID=81648879
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112023021803A BR112023021803A2 (pt) | 2021-04-20 | 2022-04-20 | Composição farmacêutica compreendendo o composto smtp-7 |
Country Status (7)
| Country | Link |
|---|---|
| EP (1) | EP4326258A1 (pt) |
| KR (1) | KR20230173129A (pt) |
| CN (1) | CN117279634A (pt) |
| AU (1) | AU2022262593A1 (pt) |
| BR (1) | BR112023021803A2 (pt) |
| CA (1) | CA3214630A1 (pt) |
| WO (1) | WO2022226013A1 (pt) |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP4313049B2 (ja) | 2003-01-23 | 2009-08-12 | 株式会社ティーティーシー | 血管新生関連疾患の予防又は治療用医薬組成物 |
| JP2004224737A (ja) | 2003-01-23 | 2004-08-12 | Ttc:Kk | 新規トリプレニルフェノール化合物 |
| US20090270476A1 (en) | 2005-10-06 | 2009-10-29 | Keiji Hasumi | Pharmaceutical composition for treatment or prevention of nephritis and manufacturing method thereof |
| ES2543573T3 (es) | 2006-03-27 | 2015-08-20 | Tokyo University Of Agriculture And Technology Tlo | Compuestos de triprenilfenol, proceso para su producción y uso como potenciador de la trombólisis |
| ES2476041T3 (es) | 2009-07-06 | 2014-07-11 | National University Corporation Tokyo University Of Agriculture And Technology | Agente citoprotector trifenilfen�lico |
| WO2011125930A1 (ja) | 2010-04-02 | 2011-10-13 | 日本製薬株式会社 | 炎症性腸疾患又は自己免疫性の末梢神経障害の予防又は治療剤 |
-
2022
- 2022-04-20 WO PCT/US2022/025462 patent/WO2022226013A1/en active Application Filing
- 2022-04-20 BR BR112023021803A patent/BR112023021803A2/pt unknown
- 2022-04-20 EP EP22723282.4A patent/EP4326258A1/en active Pending
- 2022-04-20 CA CA3214630A patent/CA3214630A1/en active Pending
- 2022-04-20 AU AU2022262593A patent/AU2022262593A1/en active Pending
- 2022-04-20 CN CN202280033984.6A patent/CN117279634A/zh active Pending
- 2022-04-20 KR KR1020237038571A patent/KR20230173129A/ko unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230173129A (ko) | 2023-12-26 |
| EP4326258A1 (en) | 2024-02-28 |
| CN117279634A (zh) | 2023-12-22 |
| AU2022262593A1 (en) | 2023-11-02 |
| WO2022226013A1 (en) | 2022-10-27 |
| CA3214630A1 (en) | 2022-10-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112019024831A2 (pt) | composto, sal, solvato ou pró-droga, composição farmacêutica, método de tratamento ou prevenção de uma doença, método para inibir o nlrp3 | |
| BR112023015067A2 (pt) | Composto de quinazolina para induzir a degradação de proteína kras g12d mutante | |
| BR112019005351A2 (pt) | terapia combinada com agonistas de cnp de liberação controlada | |
| BR112017003546A2 (pt) | amidas heterocíclicas como inibidores de rip1 quinase como medicamentos | |
| CO2021007447A2 (es) | Métodos de tratamiento para la fibrosis quística | |
| BR112012025390B8 (pt) | Composto de tetraidrobenzotiofeno ou sal do mesmo e seu uso no tratamento ou prevenção de hiperfosfatemia, bem como composição farmacêutica compreendendo o dito composto | |
| BRPI1012219C1 (pt) | produto, substrato, composição farmacêutica, usos de um produto, e de um peptídeo antimicrobiano, métodos para prevenir formação de biofilme em um ambiente, para tratar uma infecção microbiana por profilaxia ou terapia, e para tratar ou prevenir formação de biofilme em um ambiente, e, uso de uma cisteamina | |
| SG11201908234WA (en) | Pharmaceutical composition comprising compound capable of penetrating blood-brain barrier as effective ingredient for preventing or treating brain cancer | |
| BR112017003186A2 (pt) | composição farmacêutica para tratamento de cancer positivo para mutação em flt3, inibidor de flt3 mutante e usos dos mesmos | |
| BR112018070586A2 (pt) | compostos de pirazol[1,5-a]pirimidinil carboxamida e seu uso no tratamento de distúrbios médicos | |
| BR112021017314A2 (pt) | Uso de extrato de elaeocarpus sylvestris | |
| BR112022010323A2 (pt) | Composto, composto ou sal, medicamento, métodos para ativar um receptor tipo 2 de orexina e para prevenir ou tratar narcolepsia, e, uso do composto ou sal | |
| Fabry et al. | In-vitro activity of polyhexanide alone and in combination with antibiotics against Staphylococcus aureus | |
| IL291168A (en) | A result of heteroarylamidopyridinol and a pharmaceutical preparation containing it as an active ingredient for the prevention or treatment of autoimmune disease | |
| CL2019001746A1 (es) | Amidas aromáticas de ácido carboxílico | |
| BR112015019802A2 (pt) | formulações farmacêuticas de nitrito e usos das mesmas | |
| BR112023021803A2 (pt) | Composição farmacêutica compreendendo o composto smtp-7 | |
| BR112023000770A2 (pt) | Inibidor de egfr | |
| BR112019024804A2 (pt) | compostos bicíclicos 5,6-fundidos e composições para o tratamento de doenças parasíticas | |
| BR112020021631A8 (pt) | Composto oxo-substituído | |
| BR112017016278A2 (pt) | agente preventivo e/ou terapêutico de doença imune | |
| BR112018004249A2 (pt) | composto, e, composição para prevenção ou tratamento de doenças trombóticas. | |
| BR112014025973A2 (pt) | preparação e método para prevenir e tratar a osteoporose e fraturas ósseas | |
| BR112021011293A2 (pt) | Composição farmacêutica para prevenção ou tratamento de câncer compreendendo lactobacillus sakei wikim30 como ingrediente ativo | |
| BR112019025478A8 (pt) | Combinação de regorafenib e inibidores de pd-1/pd-l1(2) para tratamento de câncer |